Status: current, Defined. Date: 31-Jul 2021. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 4555689017 | Product containing precisely ponatinib (as ponatinib hydrochloride) 30 milligram/1 each conventional release oral tablet (clinical drug) | en | Fully specified name | Active | Case insensitive | SNOMED CT core |
| 4555690014 | Ponatinib (as ponatinib hydrochloride) 30 mg oral tablet | en | Synonym | Active | Case insensitive | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Ponatinib (as ponatinib hydrochloride) 30 mg oral tablet | Has precise active ingredient | Ponatinib hydrochloride | true | Inferred relationship | Some | 1 | |
| Ponatinib (as ponatinib hydrochloride) 30 mg oral tablet | Is a | Ponatinib only product in oral dose form | true | Inferred relationship | Some | ||
| Ponatinib (as ponatinib hydrochloride) 30 mg oral tablet | Has BoSS | Ponatinib | true | Inferred relationship | Some | 1 | |
| Ponatinib (as ponatinib hydrochloride) 30 mg oral tablet | Has unit of presentation | Tablet | true | Inferred relationship | Some | ||
| Ponatinib (as ponatinib hydrochloride) 30 mg oral tablet | Plays role | Antineoplastic therapeutic role | true | Inferred relationship | Some | ||
| Ponatinib (as ponatinib hydrochloride) 30 mg oral tablet | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 1 | |
| Ponatinib (as ponatinib hydrochloride) 30 mg oral tablet | Has presentation strength denominator unit | Tablet | true | Inferred relationship | Some | 1 | |
| Ponatinib (as ponatinib hydrochloride) 30 mg oral tablet | Has manufactured dose form | Conventional release oral tablet | true | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR